History of Chugai Pharmaceutical
Understanding Chugai’s history that fostered the business philosophy “Innovation all for the patients”
- Foundation - 1939
- 1940 - 1959
- 1960 - 1979
- 1980 - 1999
- 2000 - 2019
- 2020 -
Chugai merged with Nippon Roche in 2002 based on a strategic alliance agreement with Roche.
- History of Chugai Pharmaceutical
- History of Nippon Roche
J.C. Froidevaux appointed as Representative Director and President
Launched Alfarol®, an active vitamin D3 derivative (Jan.)
Started research and development of treatment for rheumatoid arthritis
Launched Madopar®, an anti-Parkinsonism agent (Feb.)
Opened New York office (Oct.)
Purchased equity of a US venture, Genetics Institute Inc. (Oct.)
Start of the collaborative research on IL-6 inhibitors (now Actemra®) with Osaka University
Opened London office (Mar.)
Launched Rocephin®, a cephem antibiotic agent (Aug.)
Hajime Sano appointed as Representative Director and President (Mar.)
Constructed the Fuji-Gotemba Research Laboratory (Shizuoka Prefecture) (Jun.)
Established Diagnostics Headquarters (Mar.)
Acquired Gen-Probe Incorporated (United States) (Dec.)
R.A. Meyer appointed as Representative Director and President
Constructed the Utsunomiya Plant (Tochigi Prefecture) (Oct.)
Established C&C Research Laboratories in Korea (Jan.)
Osamu Nagayama appointed as Representative Director and President (Sep.)
Chugai announced “the vision of 21st century”
Hiroaki Shigeta appointed as Representative Director and President
Converted the London office (opened March 1986) into Chugai Pharma Europe Ltd., an overseas subsidiary (United Kingdom) (Jan.)
Established Chugai Diagnostics Science Co., Ltd. (Tokyo) (Mar.)
Established Chugai Pharma Marketing Ltd. (United Kingdom, now Chugai Pharma Europe Ltd.) (Dec.)
Established Roche Vitamin Japan K.K. (Feb.)
Spun-off the Diagnostics Headquarters as Roche Diagnostics K.K. (Aug.)
Launched CellCept® an immunosuppressant agent (Nov.)
- Foundation - 1939
- 1940 - 1959
- 1960 - 1979
- 1980 - 1999
- 2000 - 2019
- 2020 -
